Patents Examined by Ronald T Niebauer
  • Patent number: 10377813
    Abstract: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: August 13, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Geoffry L. Curran, Gobinda Sarkar, Joseph F. Poduslo, Robert B. Jenkins, Val J. Lowe, Eric W. Mahlum
  • Patent number: 10377699
    Abstract: A method for the synthesis of daptomycin or a daptomycin analog is carried out on a resin to form a linear precursor followed by a serine ligation macrocyclization in solution. Daptomycin analogs can differ from daptomycin by substitution of amino acids residues and/or deletion or addition of amino acid residues. Daptomycin analogs can include a different fatty acid in the side arm of the daptomycin analog.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 13, 2019
    Assignee: The University of Hong Kong
    Inventors: Xuechen Li, Hiu Yung Lam
  • Patent number: 10350162
    Abstract: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: July 16, 2019
    Assignee: Oramed Ltd.
    Inventor: Miriam Kidron
  • Patent number: 10329341
    Abstract: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n,where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix is increased due solely to steric effects relative to prior known collagen-related triple helices. Methods are also disclosed for making the novel collagen mimics.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 25, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Matthew D. Shoulders, Jonathan A. Hodges
  • Patent number: 10322998
    Abstract: Disclosed are isolated, unnatural polypeptides containing cyclically-constrained ?-amino acid residues and cyclically-constrained ?-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Samuel H. Gellman, Ahlke Hayen, Margaret A. Schmitt, Felix N. Ngassa
  • Patent number: 10323065
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 18, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10316062
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10314880
    Abstract: The present invention relates to ready to dilute injectable formulations of bortezomib comprising bortezomib, non-aqueous solvents enhancing the solubility and pH modifying agent.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 11, 2019
    Inventors: P. Kanteepan, Sagar Laxmanbhai Vekariya, Jayanta Kumar Mandal, Sandip P. Mehta
  • Patent number: 10314776
    Abstract: The present invention relates to the field of dental care, in particular, to a dental care product such as toothpaste (dentifrice), prophylactic paste, tooth powder, tooth polish, tooth gel, chewing gum, candy, lozenge, mouthwash, whitening strip, coated dental floss, coated toothbrush, paint-on gel, varnish, veneer, and tube, syringe or dental tray comprising a gel or paste, mouthwash, whitening strips and trays for whitening teeth, wherein the product comprises mineral particles such as crystals and a compound, preferably, a protein capable of forming a matrix which is a hydrogel, wherein the product comprises a fluorophore. The mineral particles may comprise, e.g., calcium phosphate, preferably, hydroxyapatite, preferably, in crystalline form. The protein matrix may comprise, e.g., a self-assembling peptide. The product also comprises a fluorophore, which may be a fluorescent amino acid residue of the protein matrix.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: June 11, 2019
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek, Karl-Heinz Kunzelmann
  • Patent number: 10316063
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10308699
    Abstract: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: June 4, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Noriyuki Kawahata, Vincent Guerlavais, Manoj Samant
  • Patent number: 10307509
    Abstract: The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: June 4, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Andreas Goessl, Katarzyna Gorna
  • Patent number: 10301352
    Abstract: We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.
    Type: Grant
    Filed: August 23, 2014
    Date of Patent: May 28, 2019
    Assignee: UNIWERSYTET WARSZAWSKI
    Inventors: Aleksandra Misicka-Kęsik, Dagmara Tymecka, Bartlomiej Fedorczyk, Piotr Sosnowski, Beata Wileńska, Ewa Witkowska, Patrick Ladam, Gerard Y. Perret, Anna Starzec
  • Patent number: 10266612
    Abstract: A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells while maintaining their pluripotency/multipotency.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 23, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Victor Nurcombe, Simon Cool
  • Patent number: 10258695
    Abstract: Methods and reagents for enhancing cellular uptake of a cargo molecule by covalently bonding optionally-substituted fluorenyl groups to the cargo molecules, where cellular uptake includes at least partial uptake into the cytosol. Useful fluorenylation reagents include those of formula: and salts thereof where variables are as defined. Cargo molecules include peptides and proteins. Also provided are fluorenylated cargo molecules, including fluorenylated peptides and proteins.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 16, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Kristen A. Andersen
  • Patent number: 10226507
    Abstract: The present invention relates to alpha-1-microglobulin for use in the treatment of a mitochondria-related disease.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: March 12, 2019
    Assignee: A1M PHARMA AB
    Inventors: Bo Åkerstrom, Magnus Gram, Lena Rosenlöf
  • Patent number: 10227562
    Abstract: Motile particles are sorted from non-motile particles in a microfluidic sorting device wherein a stream of sort fluid containing motile and non-motile particles is caused to flow adjacent a media stream in non-turbulent fashion through a sort channel, during which flow motile particles cross the interface between the adjacent flow streams, entering the media stream, and forming a motile particle-depleted sort stream. The sorting devices are easily and inexpensively fabricated and have numerous uses, in particular sorting of motile from non-motile sperm.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shuichi Takayama, Gary D. Smith, Timothy G. Schuster, Brenda S. Cho
  • Patent number: 10220073
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: March 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Patent number: 10203323
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 12, 2019
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 10202416
    Abstract: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 12, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler